Dr. Kerry B. Goralski, PhD
Professor, College of Pharmacy, and Cross Appointment to Department of Pharmacology
Development of new anti-cancer drugs for drug resistant metastatic breast cancer, obesity and endocrine function of fat tissue, preclinical and clinical pharmacology and pharmacokinetics, drug transport and metabolism
Membrane drug pumps and multidrug resistant metastatic breast cancer
Multidrug resistance remains a serious problem in the effective treatment of metastatic breast cancer. One way that breast cancer cells develop resistance is by increasing their number of cell membrane drug pumps (e.g. P-glycoprotein) that remove helpful chemotherapy from the inside of cancer cells. Our research has shown that a class of bacterial-derived natural product molecules called jadomycins escape P-glycoprotein function, allowing them to kill cultured breast cancer cells that are resistant to other chemotherapy drugs. Our current pharmacological research focuses on determining how jadomycins kill breast cancer cells, if jadomycins kill breast cancer cells without harming noncancerous cells and if jadomycins prevent breast cancer growth and metastasis in zebrafish and mouse experimental models. Through this research, we can better understand how jadomycins could be used to treat patients in a clinical setting, and also learn more about metastatic breast cancer as a disease.
Membership Status:Dr. Goralski is a BHCRI Associate Member
Address:College of Pharmacy, Dalhousie University, 5968 College Street, Halifax, Nova Scotia, Canada, B3H 4R2
Parlee SD, Wang Y, Poirier P, Lapointe M, Martin J, Bastien M, Cianflone C and Goralski KB. Biliopancreatic diversion with duodenal switch modifies plasma chemerin in the early and long-term post-operative periods. Obesity. 2015: 23,1201-1208. epub 2015 May 9.
Hall SR, Blundon HL, Ladda MA, Robertson AW, Martinez-farina CF, Jakeman DL and Goralski KB. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism. Pharmacology Research and Perspectives. 2015: 3(2). Published online Feb 2, 2015.
Willson J-A*, Goralski KB*, Soroka MD, Morrison M, Mossop RN, Sleno L, Wang Y and Anderson DR. An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol, Epub, May 21, 2014. * equally contributing authors.
Issa ME, Hall SH, Dupuis SN, Graham Cl, Jakeman DL and Goralski KB. Jadomycin cytotoxicity in MCF7 breast cancer cells is independent of ABCB1, ABCC1 or ABCG2 efflux transporter function.Anticancer Drugs. 2014: 25, 255-269. Epub Nov 14, 2013.
Parlee SD, McNeil JO, Muruganandan S, Sinal CJ and Goralski KB. Elastase and tryptase govern TNFmediated production of bioactive chemerin by adipocytes. Plos 1. Epub Dec 5, 2012.
Issa ME, Muruganandan S, Ernst ME, Parlee SD, Zabel BA, Butcher EC, Sinal CJ and Goralski KB. CMKLR1 regulates skeletal muscle myogenesis. Am J Physiol-Cell Physiol. 2012: 302, C1621-31. Epub 2012, March 28.
Dupuis SN, Veinot T, Douglas SE, Syvitski RT, Goralski KB, Mcfarland AM, Jakeman DL. Synthetic diversification of natural products: semi-synthesis and evaluation of triazole jadomycins. Chem Sci 2012: 3, 1640-1644. Epub 2012, Jan 31.
Thorne-Humphrey L*, Goralski KB*, Slayter K, Johnston L, Hatchette T and McNeil S. Oseltamivir pharmacokinetics in morbid obesity (OPTIMO Trial). J Antimicrob Chemother. 2011: 66, 2083-2091. Epub 2011, June 13. *Equal contributing authors.
Muruganandan S, Parlee SD, Ernst MC, Rourke J, Goralski KB and Sinal CJ. Regulation of chemerin by PPAR: impact on the adipogenic differentiation program of mesenchymal progenitor cells. J Biol Chem 2011, 286: 23982-23995. Epub 2011 May 14.
Parlee SD, Ernst M, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and TNF. Endocrinology. 2010: 151, 2590-602. Epub 2010 Apr 2.